^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-8902

    i
    Other names: JNJ-8902, JNJ-70218902, JNJ-902
    Associations

    News

    Trials
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, TMEFF2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=52, Enrolling by invitation, Janssen Research & Development, LLC | N=35 --> 52
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    9d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=120, Enrolling by invitation, Janssen Research & Development, LLC | N=80 --> 120
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    15d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC | Trial completion date: Jan 2028 --> Oct 2028
    Trial completion date
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    2ms
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    JNJ-8902
    9ms
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    JNJ-8902
    1year
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2025 --> Oct 2025
    Trial completion date
    |
    JNJ-8902
    1year
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC
    New P1 trial
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    over1year
    A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. (PubMed, Oncologist)
    In this study, dose escalation was limited by emerging dose-limiting toxicities. Although a recommended phase II dose was not determined, findings indicate TMEFF2 to be a potential target in mCRPC that warrants further investigation.
    P1 data • Journal
    |
    EGF (Epidermal growth factor) • TMEFF2 (Transmembrane Protein With EGF Like And Two Follistatin Like Domains 2)
    |
    JNJ-8902
    over1year
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    JNJ-8902
    over1year
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Jun 2025
    Trial completion date
    |
    JNJ-8902
    over2years
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Sep 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    JNJ-8902
    almost3years
    A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2023 --> Sep 2023
    Trial completion date • Metastases
    |
    JNJ-8902